Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2004 1
2006 6
2007 9
2008 8
2009 6
2010 7
2011 19
2012 10
2013 12
2014 18
2015 11
2016 6
2017 12
2018 8
2019 4
2020 11
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

136 results
Results by year
Filters applied: . Clear all
Page 1
Lysosomal storage diseases.
Ferreira CR, Gahl WA. Ferreira CR, et al. Transl Sci Rare Dis. 2017 May 25;2(1-2):1-71. doi: 10.3233/TRD-160005. Transl Sci Rare Dis. 2017. PMID: 29152458 Free PMC article. Review.
Examples include imiglucerase, taliglucerase and velaglucerase for Gaucher disease, laronidase for Hurler disease, idursulfase for Hunter disease, elosulfase for Morquio disease, galsulfase for Maroteaux-Lamy disease, alglucosidase alfa for Pompe disease, and agalsidase al …
Examples include imiglucerase, taliglucerase and velaglucerase for Gaucher disease, laronidase for Hurler disease, idursulfase for Hu …
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA, Kimura A. Whiteman DA, et al. Drug Des Devel Ther. 2017 Aug 23;11:2467-2480. doi: 10.2147/DDDT.S139601. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28860717 Free PMC article. Review.
Preclinical studies utilizing the intravenous route of administration provided valuable insights that informed the design of the subsequent clinical studies. The pivotal Phase II/III clinical trial of intravenous idursulfase (Elaprase(); Shire, Lexington, MA, USA) demonstr …
Preclinical studies utilizing the intravenous route of administration provided valuable insights that informed the design of the subsequent …
Idursulfase.
[No authors listed] [No authors listed] 2021 Jun 21. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. 2021 Jun 21. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. PMID: 29999666 Free Books & Documents. Review.
No information is available on the clinical use of idursulfase during breastfeeding. Because it is a large protein molecule with a molecular weight of about 76,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed i …
No information is available on the clinical use of idursulfase during breastfeeding. Because it is a large protein molecule with a mo …
Mucopolysaccharidosis Type II.
Scarpa M. Scarpa M. 2007 Nov 6 [updated 2018 Oct 4]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. 2007 Nov 6 [updated 2018 Oct 4]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. PMID: 20301451 Free Books & Documents. Review.
Prevention of primary manifestations: Weekly enzyme replacement therapy (ERT) with infusions of idursulfase (Elaprase()), a recombinant form of human iduronate 2-sulfatase, is approved to treat somatic manifestations and prolong survival. ...
Prevention of primary manifestations: Weekly enzyme replacement therapy (ERT) with infusions of idursulfase (Elaprase()), a recombina …
Mucopolysaccharidosis type II, Hunter's syndrome.
Tylki-Szymańska A. Tylki-Szymańska A. Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:107-13. Pediatr Endocrinol Rev. 2014. PMID: 25345092 Review.
Limited experience of Haematopoietic stem cell therapy in MPS II showed progressive neurodegeneration. Recombinant 125 Idursulfase, is indicated for long-term treatment. The response appears to depend on the severity of the disease and the age treatment is started, Improve …
Limited experience of Haematopoietic stem cell therapy in MPS II showed progressive neurodegeneration. Recombinant 125 Idursulfase, i …
Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
Okuyama T, Eto Y, Sakai N, Minami K, Yamamoto T, Sonoda H, Yamaoka M, Tachibana K, Hirato T, Sato Y. Okuyama T, et al. Mol Ther. 2019 Feb 6;27(2):456-464. doi: 10.1016/j.ymthe.2018.12.005. Epub 2018 Dec 8. Mol Ther. 2019. PMID: 30595526 Free PMC article. Clinical Trial.
Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglycans, giving rise to multiple systemic and CNS symptoms. The currently available therapies, idursulfase and idursulfase beta, ar …
Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglyca …
Idursulfase in Hunter syndrome treatment.
Zareba G. Zareba G. Drugs Today (Barc). 2007 Nov;43(11):759-67. doi: 10.1358/dot.2007.43.11.1157619. Drugs Today (Barc). 2007. PMID: 18174963 Review.
Results of the randomized, double-blind, placebo-controlled phase II/III clinical trial of idursulfase demonstrated that weekly infusions of idursulfase increase walking distance and improve pulmonary function as well as reduce organ size and urinary glycosaminoglyc …
Results of the randomized, double-blind, placebo-controlled phase II/III clinical trial of idursulfase demonstrated that weekly infus …
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis.
Bender TTA, Leyens J, Sellin J, Kravchenko D, Conrad R, Mücke M, Seidel MF. Bender TTA, et al. Orphanet J Rare Dis. 2020 Oct 31;15(1):308. doi: 10.1186/s13023-020-01576-5. Orphanet J Rare Dis. 2020. PMID: 33129321 Free PMC article. Review.
The pharmacotherapies tested in these studies consisted of immunosuppressants, such as corticosteroids, methotrexate and azathioprine, or biologicals. We found solid evidence for idursulfase as a treatment for Hunter syndrome. In Behcet's disease, apremilast and IF-alpha s …
The pharmacotherapies tested in these studies consisted of immunosuppressants, such as corticosteroids, methotrexate and azathioprine, or bi …
Idursulfase: I2S, iduronato-2-sulfatase.
[No authors listed] [No authors listed] Drugs R D. 2006;7(4):254-8. doi: 10.2165/00126839-200607040-00005. Drugs R D. 2006. PMID: 16784250 Review. No abstract available.
136 results